Endocrine Abstracts

Background: Peptide Receptor Radionuclide Therapy (PRRT) is effective for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and received FDA approval after demonstrating improved progression-free-survival (PFS) in advanced midgut NETs. We investigated a two-decade experience with PRRT, hypothesizing that PRRT confers PFS and overall-survival (OS) advantages in patients who progress after surgery.Methods: A single-institutional NET database was re...

Background: Carcinoid syndrome (CS), the most common functional neuroendocrine tumor (NET) syndrome, is characterized by watery diarrhea or cutaneous flushing. While somatostatin receptor ligand (SRL) depot injections are mainstay treatments for CS, discomfort with injections and inadequate symptom relief at labeled doses are seen with many patients. Paltusotine is an investigational once-daily, oral, selective SST2 agonist in development for the treatment of acromegaly and CS...

Background: Small bowel neuroendocrine tumors (SBNETs) originate from enterochromaffin cells in the intestine which synthesize and secrete serotonin. Other NETs and other cancers may also produce serotonin but do not store them in vesicles. The rate limiting enzyme of serotonin biosynthesis is tryptophan hydroxylase 1 (Tph1). Patients with high serotonin level could develop carcinoid syndrome, which can be treated with somatostatin analogues and the Tph1 inhibitor telotristat ...